Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum -Lactamase Bacteremia | Zendy

Pranita D. Tamma | Zendy; Jennifer Han | Zendy; Clare Rock | Zendy; Anthony Harris | Zendy; Ebbing Lautenbach | Zendy; Alice J. Hsu | Zendy; Edina Avdic | Zendy; Sara E. Cosgrove | Zendy

Open Access

Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum -Lactamase Bacteremia

Author(s) -

Pranita D. Tamma,

Jennifer Han,

Clare Rock,

Anthony Harris,

Ebbing Lautenbach,

Alice J. Hsu,

Edina Avdic,

Sara E. Cosgrove

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ003

Subject(s) - medicine , bacteremia , carbapenem , tazobactam , piperacillin/tazobactam , hazard ratio , piperacillin , empiric therapy , proportional hazards model , confidence interval , antibiotics , intensive care medicine , antibiotic resistance , imipenem , microbiology and biotechnology , genetics , alternative medicine , pathology , bacteria , pseudomonas aeruginosa , biology

The effectiveness of piperacillin-tazobactam (PTZ) for the treatment of extended-spectrum β-lactamase (ESBL) bacteremia is controversial. We compared 14-day mortality of PTZ vs carbapenems as empiric therapy in a cohort of patients with ESBL bacteremia who all received definitive therapy with a carbapenem.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research